共找到 20 条结果
暂无摘要（点击查看原文获取完整内容）
暂无摘要（点击查看原文获取完整内容）
暂无摘要（点击查看原文获取完整内容）
Because it is given intravenously at the end of dialysis, Parsabiv could be the answer to the adherence problems posed by cinacalcet. Most patients are pretty adherent to dialysis. One study found that people missed only 7.1 episodes of dialysis per patient-year, which isn't perfect but it's certainly better than adherence to self-administered drugs.
暂无摘要（点击查看原文获取完整内容）
暂无摘要（点击查看原文获取完整内容）
暂无摘要（点击查看原文获取完整内容）
Abstract Price and quality are positively related in people's minds. Saying a product costs more ought to lead to higher expectations of quality and liking. Importantly, this price‐quality heuristic is argued to affect perceived quality and liking—known as the marketing placebo effect. To investigate the robustness of this effect, we conducted six studies (total N = 2842; with students from an international Dutch university and US participants from Prolific and MTurk)—expanding on previous methodological approaches with larger samples and using products not commonly investigated in previous research. In all our studies, higher prices led to higher quality and liking expectations as suggested by the price‐quality heuristic. However, we did not find a consistent effect on perceived quality and liking once people experienced the product. Our data imply that the marketing placebo effect may be less robust or generalizable as previously assumed. This (in)efficacy should bring marketers to pause on when and whether to rely on it at all.
暂无摘要（点击查看原文获取完整内容）
This study comprehensively analyzes herding behavior in the cryptocurrency market. First, we conduct an in-depth investigation of herding behavior in the overall cryptocurrency market. Second, we form several groups of cryptocurrencies according to their characteristics and analyze whether each group behaves similarly in volatile market regimes. Third, we investigate whether herding existed in each cryptocurrency group before and during the COVID-19 pandemic. Using a sample of 227 cryptocurrencies constituting nearly 95% of market capitalization, we reveal that herding behavior was absent in the overall sample and sub-samples comprising cryptocurrency groups. Further, the anti-herding behavior implies a contrarian response to the crowd. This anti-herding can be explained from two views: rational behavior of taking profit from market irrationality and irrational behavior due to fear or recency bias.
The growing demand for highly priced marine ornamental species has contributed to the endangered status of coral reefs. A list of 128 of the most heavily traded marine ornamental decapod crustacean species is tabulated. The development of commercial culture techniques, the knowledge of the larval development, and the association with vertebrate and invertebrate organisms are presented for these species. Forty-nine of the species are caridean shrimp, with the Hippolytidae family alone accounting for 15. Anomuran and brachyuran crabs are the next most traded groups (32 and 27 species, respectively), with the pricey stenopodidean shrimp, Astacidea, and Palinura lobsters being represented by a considerably lower number of species (7, 7 and 6, respectively). The main bottlenecks impairing the commercial culture of ornamental shrimp and lobsters are their long larval development and poor survival rates. The main constraint for the development of culture techniques for hermit and brachyuran crabs is their low commercial value. The ecological impacts of harvesting ornamental species are still poorly studied. Nevertheless, the collection in considerable numbers of hermit and small majid crabs (e.g., Clibanarius and Mithraculus) from tidal areas, fish cleaning shrimp (e.g., Lysmata and Stenopus), and the crown-of-thorns sea star eaters Hymenocera, is likely to have serious impacts on the ecosystem. The cooperation between researchers working on larval biology, population dynamics, ecology, aquaculture, and fisheries is essential to properly manage the collection of marine ornamental decapods.
The Ionising Radiations Regulations 2017 require employers to restrict radiation doses to their employees and the public to be As Low As Reasonably Practicable. This article looks at the boundary between what might be considered to be reasonable and unreasonable in protecting staff and the general public in the field of hospital-based diagnostic radiology. A simple test for locating this boundary based on a cost-benefit approach is devised and its use illustrated using hospital-based radiation protection examples. It is concluded that a cost-benefit calculation based on the legal definition of As Low As Reasonably Practicable may have some use in the support of radiation protection decision-making in the hospital environment, but only within the context of existing legal, practical and ethical considerations.
Software companies need to support continuous and fast delivery of customer value both in short and a long-term perspective. However, this can be hindered by evolution limitations and high maintenance efforts due to internal software quality issues by what is described as Technical Debt. Although significant theoretical work has been undertaken to describe the negative effects of Technical Debt, these studies tend to have a weak empirical basis and often lack quantitative data. The aim of this study is to estimate wasted time, caused by the Technical Debt interest during the software life-cycle. This study also investigates how practitioners perceive and estimate the impact of the negative consequences due to Technical Debt during the software development process. This paper reports the results of both an online web-survey provided quantitative data from 258 participants and follow-up interviews with 32 industrial software practitioners. The importance and originality of this study contributes and provides novel insights into the research on Technical Debt by quantifying the perceived interest and the negative effects it has on the software development life-cycle. The findings show that on average, 36% of all development time is estimated to be wasted due to Technical Debt; Complex Architectural Design and Requirement Technical Debt generates most negative effect; and that most time is wasted on understanding and/or measuring the Technical Debt. Moreover, the analysis of the professional roles and the age of the software system in the survey revealed that different roles are affected differently and that the consequences of Technical Debt are also influenced by the age of the software system.
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
暂无摘要（点击查看原文获取完整内容）
without the requirement of a pricey instrument or highly-trained personnel.
Just five or six years ago, the term "green building" evoked visions of barefoot, tie-dyed, granola-munching denizens. There's been a large shift in perception. Of course, green buildings are still known for conserving natural resources by, for example, minimizing on-site grading, using alternative materials, and recycling construction waste. But people now see the financial advantages as well. Well-designed green buildings yield lower utility costs, greater employee productivity, less absenteeism, and stronger attraction and retention of workers than standard buildings do. Green materials, mechanical systems, and furnishings have become more widely available and considerably less expensive than they used to be-often cheaper than their standard counterparts. So building green is no longer a pricey experiment; just about any company can do it on a standard budget by following the ten rules outlined by the author. Reliable building-rating systems like the U.S. Green Building Council's rigorous Leadership in Energy and Environmental Design (LEED) program have done much to underscore the benefits of green construction. LEED evaluates buildings and awards points in several areas, such as water efficiency and indoor environmental quality. Other rating programs include the UK's BREEAM (Building Research Establishment's Environmental Assessment Method) and Australia's Green Star. Green construction is not simply getting more respect; it is rapidly becoming a necessity as corporations push it fully into the mainstream over the next five to ten years. In fact, the author says, the owners of standard buildings face massive obsolescence. To avoid this problem, they should carry out green renovations. Corporations no longer have an excuse for eschewing environmental and economic sustainability. They have at their disposal tools proven to lower overhead costs, improve productivity, and strengthen the bottom line.
Every company makes choices about the channels it will use to go to market. Traditionally, the decision to sell through a discount superstore or a pricey boutique, for instance, was guided by customer demographics. A company would identify a target segment of buyers and go with the channel that could deliver them. It was a fair assumption that certain customer types were held captive by certain channels--if not from cradle to grave, then at least from initial consideration to purchase. The problem, the authors say, is that today's customers have become unfettered. As their channel options have proliferated, they've come to recognize that different channels serve their needs better at different points in the buying process. The result is "value poaching." For example, certain channels hope to use higher margin sales to cover the cost of providing expensive high-touch services. Potential customers use these channels to do research, then leap to a cheaper channel when it's time to buy. Customers now hunt for bargains more aggressively; they've become more sophisticated about how companies market to them; and they are better equipped with information and technology to make advantageous decisions. What does this mean for your go-to-market strategy? The authors urge companies to make a fundamental shift in mind-set toward designing for buyer behaviors, not customer segments. A company should design pathways across channels to help its customers get what they need at each stage of the buying process--through one channel or another. Customers are not mindful of channel boundaries--and you shouldn't be either. Instead, they are mindful of the value of individual components in your channels--and you should be, too.
To create novel treatments and treat complex diseases, the pharmaceutical sector is essential. Drug discovery, however, is a time-consuming, pricey, and dangerous endeavor. Artificial intelligence (AI) has become a potent instrument that has transformed several industries, including healthcare, in recent years. This summary gives a general overview of how AI is expediting the creation of novel medicines, revolutionizing the pharmaceutical sector, and enabling drug discovery. The pharmaceutical sector is experiencing a drug discovery revolution because of AI. The drug discovery process is changing at different phases because of AI approaches like machine learning and deep learning. This abstract demonstrates how AI facilitates drug development through target identification, lead compound optimization, drug design, drug repurposing, and clinical trial enhancement. AI integration has the potential to hasten the creation of novel treatments, save costs, and improve patient outcomes. To fully realize the potential of AI in pharmaceutical research and development, issues relating to data accessibility, algorithm interpretability, and laws must be resolved.
暂无摘要（点击查看原文获取完整内容）